Financings
NeuroThera Labs Announces C$5,000,000 Private Placement of Units
Pre-revenue neurology and cannabis-tech company raises capital at a discount to fund operations and settle parent company debt.
Executive Summary
- NeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at C$0.135 per unit, targeting gross proceeds of approximately C$5,000,000.
- Each unit consists of one common share and one transferable common share purchase warrant.
- Warrants are exercisable at C$0.18 per share for a 24-month term.
- Proceeds are designated for general working capital, evaluation of prospective transactions, settlement of liabilities, and repayment of indebtedness to parent company SciSparc Ltd.
- Closing is subject to TSX Venture Exchange approval and standard regulatory conditions.
- Securities carry a statutory hold period of four months and one day.
Material Impact
- The financing is dilutive, introducing ~37 million new shares and an equal number of warrants to the capital structure.
- The placement price of C$0.135 represents a ~20% discount to the recent trading range of $0.16–$0.18, which typically pressures the stock downward toward the placement price in the short term.
- The warrant strike price of $0.18 is currently out-of-the-money, limiting immediate secondary dilution from warrant exercises.
- Use of proceeds to repay debt to SciSparc Ltd. highlights a related-party funding dynamic, reducing the company's independent cash runway but alleviating immediate liquidity pressure.
- The transaction does not alter the company's pre-revenue status or commercial pipeline timeline. It is a standard survival financing for a micro-cap biotech.
NTLX · Price
Company Overview
- NeuroThera Labs Inc. is a pre-revenue biotechnology company focused on neurology, pain management, and cannabinoid-based therapeutics.
- Core pipeline includes MEAI+PEA combination therapies for depression, obesity, and addiction, developed in collaboration with Clearmind Medicine.
- The company also holds patents for cannabinoid-antibiotic combinations targeting antimicrobial resistance (MRSA) and opioid-PEA formulations for pain relief.
- In June 2026, the company closed the acquisition of a majority stake in CliniQuantum Ltd., a quantum simulation and Monte Carlo methods firm aimed at accelerating clinical trial data analysis.
- The company is effectively controlled by SciSparc Ltd., which acquired a ~75% stake via a reverse takeover in October 2025.
More from NeuroThera Labs Inc.
Jun 03, 2026 · 17:15